UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Codon-specific translation reprogramming promotes resistance to targeted therapy

Nature (London), 2018-06, Vol.558 (7711), p.605-609

2018

Volltextzugriff (PDF)

Cemiplimab for locally advanced and metastatic basal cell carcinoma

Expert review of anticancer therapy, 2022-03, Vol.22 (3), p.243-248

2022

Volltextzugriff (PDF)

Melanoma masquerading as nonmelanocytic lesions

Melanoma research, 2016-12, Vol.26 (6), p.631-634

2016

Volltextzugriff (PDF)

Oncological patients' reactions to COVID‐19 pandemic: A single institution prospective study

Cancer reports, 2022-10, Vol.5 (10), p.e1571-n/a

2022

Volltextzugriff (PDF)

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy

Case reports in dermatology, 2019-01, Vol.11 (1), p.101-107

2019

Volltextzugriff (PDF)

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma

Anticancer research, 2015-12, Vol.35 (12), p.6893-6899

2015

Volltextzugriff (PDF)

Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel

Expert review of anticancer therapy, 2021-04, Vol.21 (4), p.355-363

2021

Volltextzugriff (PDF)

The impact of COVID-19 on the new diagnoses of melanoma

EJD. European journal of dermatology, 2021-08, Vol.31 (4), p.565-567

2021

Volltextzugriff (PDF)

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL

Cancers, 2023-09, Vol.15 (19), p.4823

2023

Volltextzugriff (PDF)

Pre-study and in-study validation of a SPE-LC–MS–MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma

Talanta (Oxford), 2011-04, Vol.84 (2), p.280-286

2011

Volltextzugriff (PDF)

Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer

Future oncology (London, England), 2015-06, Vol.11 (12), p.1775-1789

2015

Volltextzugriff (PDF)

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes

Breast cancer targets and therapy, 2014-01, Vol.6 (default), p.43-57

2014

Volltextzugriff (PDF)

18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Nuclear medicine communications, 2011-03, Vol.32 (3), p.168-176

2011

Volltextzugriff (PDF)

Cardio-oncology and cardio-obstetrics : crucial role of a multidisciplinary approach

Revue médicale de Liège, 2023-12, Vol.78 (12), p.695

2023

Volltextzugriff (PDF)

Author Correction: Codon-specific translation reprogramming promotes resistance to targeted therapy

Nature (London), 2021-11, Vol.599 (7886), p.E14-E14

2021

Volltextzugriff (PDF)

F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Nuclear medicine communications, 2011-03, Vol.32 (3), p.168-176

2011

Volltextzugriff (PDF)

Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations

Annals of oncology, 2006-09, Vol.17 (suppl-10), p.x168-x176

2006

Volltextzugriff (PDF)

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9524-9524

2017

Volltextzugriff (PDF)

Re-biopsy in breast cancer recurrence: Is there really a clinical impact?

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e11549-e11549

2013

Volltextzugriff (PDF)

Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9526-9526

2016

Volltextzugriff (PDF)

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate

Dermatology and therapy, 2014-06, Vol.4 (1), p.131-135

2014

Volltextzugriff (PDF)

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy

Case reports in dermatology, 2019, Vol.11 (1), p.101-107

2019

Volltextzugriff (PDF)

18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Nuclear medicine communications, 2011-03, Vol.32 (3), p.168-176

2011

Volltextzugriff (PDF)

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebubate

2014

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(19)

Publikationsform

Sprache

Englisch
(25)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Codon-specific translation reprogramming promotes resistance to targeted therapy

Cemiplimab for locally advanced and metastatic basal cell carcinoma

Melanoma masquerading as nonmelanocytic lesions

Oncological patients' reactions to COVID‐19 pandemic: A single institution prospective study

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma

Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel

The impact of COVID-19 on the new diagnoses of melanoma

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL

Pre-study and in-study validation of a SPE-LC–MS–MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma

Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes

18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Cardio-oncology and cardio-obstetrics : crucial role of a multidisciplinary approach

Author Correction: Codon-specific translation reprogramming promotes resistance to targeted therapy

F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172)

Re-biopsy in breast cancer recurrence: Is there really a clinical impact?

Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172)

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy

18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebubate

Nivolumab safety in patients with advanced melanoma who have progressed on or after Ipilimumab : a single-arm, open-label, multicenter, phase II study (CheckMate 172)

Suchergebnisse filtern